SCHEMBL21686876

SCHEMBL21686876

Clc1cc2c(NCc3cccs3)nc(Cl)nc2cn1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.53
NPC1 O15118 1/20 0.51
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
ALDH1A1 P00352 4/20 0.49
MAPT P10636 2/20 0.49
KDM4E B2RXH2 2/20 0.49
CLK4 Q9HAZ1 8/20 0.48
DYRK1A Q13627 2/20 0.48
HRH1 P35367 1/20 0.48
HRH4 Q9H3N8 1/20 0.48
TSHR P16473 4/20 0.48
CYP1A2 P05177 4/20 0.48
CYP3A4 P08684 4/20 0.48
CYP2D6 P10635 4/20 0.48
CYP2C19 P33261 4/20 0.48
LMNA P02545 3/20 0.48
CYP2C9 P11712 3/20 0.48
USP2 O75604 3/20 0.48
APEX1 P27695 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30763407 1.00 SMN1; SMN2 (0.53) SMN1; SMN2NPC1MEN1KMT2AALDH1A1
SCHEMBL21686826 0.82 HRH4 (0.75) HRH1HRH4PDE5A
SCHEMBL30763423 0.82 HRH4 (0.75) HRH1HRH4PDE5A
SCHEMBL21686870 0.81 HRH4 (0.60) NPC1MEN1KMT2AALDH1A1MAPT
SCHEMBL21686911 0.81 HRH4 (0.62) NPC1MEN1KMT2AALDH1A1MAPT
SCHEMBL30763389 0.81 HRH4 (0.60) NPC1MEN1KMT2AALDH1A1MAPT
SCHEMBL3643331 0.81 MEN1 (0.70) SMN1; SMN2MEN1KMT2AALDH1A1MAPT
Hydrochloric Acid SCHEMBL23855480 0.80 HRH4 (0.59) NPC1MEN1KMT2AALDH1A1MAPT
SCHEMBL21686978 0.80 CHRM3 (0.49) SMN1; SMN2NPC1MEN1KMT2AALDH1A1
SCHEMBL21687030 0.80 HRH4 (0.59) NPC1HRH1HRH4PDE5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492199-B2 Pyridopyrimidines as histamine H4-receptor inhibitors FAES FARMA, S.A. (ES) 2025-12-09 US disclosed
EP-3827005-B1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA SA (ES) 2022-08-17 EP disclosed
US-20210300922-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA, S.A. (ES) 2021-09-30 US disclosed
US-20210300922-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA, S.A. (ES) 2021-09-30 US disclosed
WO-2020020939-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS FAES FARMA, S.A. (ES) 2020-01-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300922-A1 PYRIDOPYRIMIDINES AS HISTAMINE H4-RECEPTOR INHIBITORS HRH4, HRH3, HRH2 SMN1; SMN2 2547/4885NPC1 2970/4885MEN1 1581/4885
US-12492199-B2 Pyridopyrimidines as histamine H4-receptor inhibitors HRH4, HRH2, HRH3 SMN1; SMN2 3717/4885NPC1 1950/4885MEN1 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.